Mendelian randomization to evaluate the effect of plasma vitamin C levels on the risk of Alzheimer’s disease
Authors:
Open Access
- 29 October 2021
- journal article
- research article
- Published by Springer Nature in Genes & Nutrition
- Vol. 16 (1) , 1-17
Abstract
Objective: Until now, observational studies have explored the impact of vitamin C intake on Alzheimer’s disease (AD) risk, however, reported ambiguous findings. To develop effective therapies or prevention, the causal link between vitamin C levels and AD should be established. Methods: Here, we selected 11 plasma vitamin C genetic variants from a large-scale plasma vitamin C GWAS dataset (N = 52,018) as the potential instrumental variables. We extracted their corresponding summary statistics from large-scale IGAP clinically diagnosed AD GWAS dataset (N = 63,926) and UK Biobank AD proxy phenotype GWAS dataset (N = 314,278), as well as two UK Biobank subgroups including the maternal AD group (27,696 cases of maternal AD and 260,980 controls) and paternal AD group (14,338 cases of paternal AD and 245,941 controls). We then performed a Mendelian randomization (MR) study to evaluate the causal association between plasma vitamin C levels and the risk of AD and AD proxy phenotype. Meanwhile, we further verified these findings using a large-scale cognitive performance GWAS dataset (N = 257,841). Results: In IGAP, we found no significant causal association between plasma vitamin C levels and the risk of AD. In UK Biobank, we found that per 1 SD increase in plasma vitamin C levels (about 20.2 μmol/l) was significantly associated with the reduced risk of AD proxy phenotype (OR = 0.93, 95% CI 0.88–0.98, P = 7.00E−03). A subgroup MR analysis in UK Biobank indicated that per 1 SD increase in plasma vitamin C levels could significantly reduce the risk of AD proxy phenotype in the maternal AD group (OR = 0.89, 95% CI 0.84–0.94, P = 7.29E−05), but not in the paternal AD group (OR = 1.02, 95% CI 0.92–1.12, P = 7.59E−01). The leave-one-out permutation further showed that the SLC23A1 rs33972313 variant largely changed the precision of the overall MR estimates in all these four GWAS datasets. Meanwhile, we did not observe any significant causal effect of plasma vitamin C levels on the cognitive performance. Conclusion: We demonstrated that there may be no causal association between plasma vitamin C levels and the risk of AD in people of European descent. The insistent findings in clinically diagnosed AD and AD proxy phenotype may be caused by the phenotypic heterogeneity.Keywords
Funding Information
- National Natural Science Foundation of China (82071212, and 81901181)
This publication has 51 references indexed in Scilit:
- UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old AgePLOS Medicine, 2015
- Genetic studies of body mass index yield new insights for obesity biologyNature, 2015
- High-dose of vitamin C supplementation reduces amyloid plaque burden and ameliorates pathological changes in the brain of 5XFAD miceCell Death & Disease, 2014
- Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's diseaseNature Genetics, 2013
- Calculating statistical power in Mendelian randomization studiesInternational Journal of Epidemiology, 2012
- Antioxidants for Alzheimer DiseaseArchives of Neurology, 2012
- HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variantsNucleic Acids Research, 2011
- Genetic variation at the SLC23A1 locus is associated with circulating concentrations of l-ascorbic acid (vitamin C): evidence from 5 independent studies with >15,000 participantsThe American Journal of Clinical Nutrition, 2010
- Reduced Risk of Alzheimer Disease in Users of Antioxidant Vitamin SupplementsArchives of Neurology, 2004
- Amyloid β-protein (Aβ) assembly: Aβ40 and Aβ42 oligomerize through distinct pathwaysProceedings of the National Academy of Sciences, 2002